TY - JOUR
T1 - The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment
T2 - A New Cornerstone for Our Treatment Algorithms. Results from an International Experts Panel Meeting of the Italian Association of Thoracic Oncology
AU - Gridelli, Cesare
AU - Besse, Benjamin
AU - Brahmer, Julie Renee
AU - Crinò, Lucio
AU - Felip, Enriqueta
AU - De Marinis, Filippo
N1 - Funding Information:
C Gridelli reports honoraria as advisory board and speaker bureau member for BMS, MSD, Roche Boehringer, Eli Lilly, and a research grant from MSD. JR Brahmer reports research grants from BMS, Merck, Astra Zeneca, and advisory board compensated Merck, Eli Lilly. B Besse reports research grants from BMS. L Crinò reports consulting fees from Bristol, Boheringer, Pfizer Novartis, and Astra Zeneca. E Felip reports consulting fees from Boehringer-Ingelheim, GlaxoSmithKline, Eli Lilly, Pfizer, Roche, BMS, MSD, and Novartis. F de Marinis reports research grant from MSD and honoraria as advisory board member from BMS, Roche, Boehringer, and Novartis.
Publisher Copyright:
© 2016 Elsevier Inc.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Lung cancer is the leading cause of death from cancer worldwide that currently has only a few available treatment options in patients with no driver mutations. The therapeutic options for patients with non-small-cell lung cancer (NSCLC) who progress after first-line chemotherapy have been limited from a long time. Docetaxel has remained a cornerstone of second-line treatment for more than 20 years, but it is associated with an unfavorable safety profile. Recently, the results from immunotherapy treatment with anti-PD1 and PD-L1 inhibitors has changed our current knowledge base and increased therapeutic options for patients with NSCLC in the second-line setting. The results of 2 randomized phase III trials assessing nivolumab in lung cancer, Check-Mate-017 and Check-Mate-057, have deeply changed our current clinical practice and raised several discussion points. This paper explores the recent findings about nivolumab for the treatment of NSCLC in the second-line setting by analyzing recent trial findings and discussing their implications in clinical practice and future directions. The paper also summarizes the conclusions from an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.
AB - Lung cancer is the leading cause of death from cancer worldwide that currently has only a few available treatment options in patients with no driver mutations. The therapeutic options for patients with non-small-cell lung cancer (NSCLC) who progress after first-line chemotherapy have been limited from a long time. Docetaxel has remained a cornerstone of second-line treatment for more than 20 years, but it is associated with an unfavorable safety profile. Recently, the results from immunotherapy treatment with anti-PD1 and PD-L1 inhibitors has changed our current knowledge base and increased therapeutic options for patients with NSCLC in the second-line setting. The results of 2 randomized phase III trials assessing nivolumab in lung cancer, Check-Mate-017 and Check-Mate-057, have deeply changed our current clinical practice and raised several discussion points. This paper explores the recent findings about nivolumab for the treatment of NSCLC in the second-line setting by analyzing recent trial findings and discussing their implications in clinical practice and future directions. The paper also summarizes the conclusions from an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.
KW - Anti-PD-1 antibody
KW - Immunotherapy
KW - Nivolumab
KW - PD-L1
KW - Second-line treatment
UR - http://www.scopus.com/inward/record.url?scp=84958552083&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958552083&partnerID=8YFLogxK
U2 - 10.1016/j.cllc.2016.01.004
DO - 10.1016/j.cllc.2016.01.004
M3 - Review article
C2 - 26908078
AN - SCOPUS:84958552083
SN - 1525-7304
VL - 17
SP - 161
EP - 168
JO - Clinical lung cancer
JF - Clinical lung cancer
IS - 3
ER -